Physician profile
Peter R Wolfe
NPI 1407910201
$12,393.30
in general payments reported to CMS, 2019-2025
33 companies · $2,642 in 2025
The $2,642 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $261 · 2021: $370 · 2022: $2,045 · 2023: $2,942 · 2024: $3,171 · 2025: $2,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,755.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,501.01 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,267.32 | 2019-2025 | Biktarvy |
| Emd Serono, INC. | $1,099.20 | 2019-2025 | Serostim |
| Napo Pharmaceuticals INC | $823.11 | 2019-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $419.05 | 2022-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Biotech, INC. | $387.47 | 2019-2023 | Symtuza |
| Amgen INC. | $382.95 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.38 | 2019-2025 | Xifaxan |
| Antares Pharma, INC. | $289.26 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Bausch Health US, LLC | $287.77 | 2022-2025 | Aplenzin |
| Theratechnologies INC. | $274.87 | 2019-2024 | Trogarzo, Egrifta |
| Lilly USA, LLC | $221.63 | 2024-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $192.01 | 2023-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $155.94 | 2019-2025 | Shingrix, Arexvy |
| Abbvie INC. | $135.66 | 2021-2025 | Vraylar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $100.93 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.61 | 2024-2025 | Caplyta |
| Halozyme INC | $67.78 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.02 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $39.59 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $34.02 | 2024 | Wegovy |
| Tolmar, INC. | $32.63 | 2023-2025 | Jatenzo |
| Pfizer INC. | $31.96 | 2022-2023 | |
| Allergan, INC. | $29.64 | 2019 | |
| Boston Scientific Corporation | $26.50 | 2020 | |
| Amarin Pharma, INC. | $24.70 | 2022 | |
| Axsome Therapeutics, INC. | $21.70 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $21.40 | 2022 | |
| Ascensia Diabetes Care US INC. | $20.67 | 2025 | |
| Corcept Therapeutics | $20.29 | 2024 | Korlym |
| Acerus Pharmaceuticals Corporation | $20.09 | 2022 | |
| Seqirus USA INC | $14.20 | 2022 | |
| Vyera Pharmaceuticals, LLC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.